Muscarinic receptor subtype-specific effects on cigarette smoke-induced inflammation in mice

European Respiratory Journal

Volumn 42, Issue 6, 2013, Pages 1677-1688

  Kistemaker, Loes E M ^a,b   Bos, I Sophie T ^a,b   Hylkema, Machteld N ^b   Nawijn, Martijn C ^b   Hiemstra, Pieter S ^c   Wess, Jürgen ^d   Meurs, Herman ^a,b   Kerstjens, Huib A M ^b   Gosens, Reinoud ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; KERATINOCYTE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; INFLAMMATORY CELL; LUNG LAVAGE; LYMPHOCYTE COUNT; MACROPHAGE; MALE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY TRACT INFLAMMATION; WILD TYPE;

ACETYLCHOLINE; ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CHOLINERGIC ANTAGONISTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOTYPE; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; SMOKING;

EID: 84879092900     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00112412     Document Type: Article

References (41)

1. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8: 183-192.
3. Postma DS, Timens W. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 434-439.
4. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311: 421-425.
5. Lee AM, Jacoby DB, Fryer AD. Selective muscarinic receptor antagonists for airway diseases. Curr Opin Pharmacol 2001; 1: 223-229.
6. Kistemaker LE, Oenema TA, Meurs H, et al. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci 2012; 91: 1126-1133.
7. Roffel AF, Elzinga CR, Van Amsterdam RG, et al. Muscarinic M2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur J Pharmacol 1988; 153: 73-82.
8. Gosens R, Zaagsma J, Meurs H, et al. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006; 7: 73.
9. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 2008; 154: 1558-1571.
10. Kummer W, Lips KS, Pfeil U. The epithelial cholinergic system of the airways. Histochem Cell Biol 2008; 130: 219-234.
11. Gwilt CR, Donnelly LE, Rogers DF. The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation? Pharmacol Ther 2007; 115: 208-222.
12. Gosens R, Rieks D, Meurs H, et al. Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur Respir J 2009; 34: 1436-1443.
13. Profita M, Bonanno A, Montalbano AM, et al. Cigarette smoke extract activates human bronchial epithelial cells affecting non-neuronal cholinergic system signalling in vitro. Life Sci 2011; 89: 36-43.
14. Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFκB/ERK-dependent mechanism. Eur J Pharmacol 2008; 582: 145-153.
15. Profita M, Giorgi RD, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005; 60: 1361-1369.
16. Wollin L, Pieper MP. Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol Ther 2010; 23: 345-354.
17. Pera T, Zuidhof A, Valadas J, et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD. Eur Respir J 2011; 28: 789-796.
18. Vacca G, Randerath WJ, Gillissen A. Inhibition of granulocyte migration by tiotropium bromide. Respir Res 2011; 12: 24.
19. Fisahn A, Yamada M, Duttaroy A, et al. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation currents. Neuron 2002; 33: 615-624.
20. Gomeza J, Shannon H, Kostenis E, et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 1692-1697.
21. Yamada M, Miyakawa T, Duttaroy A, et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature 2001; 410: 207-212.
22. Bühling F, Lieder N, Kühlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 2007; 101: 2386-2394.
23. Sato E, Koyama S, Okubo Y, et al. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998; 274: L970-L979.
24. Meurs H, Dekkers BG, Maarsingh H, et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm Pharmacol Ther 2013; 26: 145-155.
25. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 1992; 262: L466-L471.
26. Reinheimer T, Möhlig T, Zimmermann S, et al. Muscarinic control of histamine release from airways. Inhibitory M1-receptors in human bronchi but absence in rat trachea. Am J Respir Crit Care Med 2000; 162: 534-538.
27. Lamb D, Lumsden A. Intra-epithelial mast cells in human airway epithelium: evidence for smoking-induced changes in their frequency. Thorax 1982; 37: 334-342.
28. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136.
29. Ishihara H, Shimura S, Satoh M, et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am J Physiol 1992; 262: L223-L228.
30. Boddeke HW, Buttini M. Pharmacological properties of cloned muscarinic receptors expressed in A9 L cells; comparison with in vitro models. Eur J Pharmacol 1991; 202: 151-157.
31. Schlenz H, Kummer W, Jositsch G, et al. Muscarinic receptor-mediated bronchoconstriction is coupled to caveolae in murine airways. Am J Physiol Lung Cell Mol Physiol 2010; 298: L626-L636.
32. Garssen J, Van Loveren H, Gierveld CM, et al. Functional characterization of muscarinic receptors in murine airways. Br J Pharmacol 1993; 109: 53-60.
33. Casarosa P, Bouyssou T, Germeyer S, et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J Pharmacol Exp Ther 2009; 330: 660-668.
34. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000; 117: Suppl. 2, 63S-66S.
35. Gosens R, Nelemans SA, Grootte Bromhaar MM, et al. Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol 2003; 28: 257-262.
36. Bos IS, Gosens R, Zuidhof AB, et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur Respir J 2007; 30: 653-661.
37. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
38. Liesker JJ, Bathoorn E, Postma DS, et al. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD. Respir Med 2011; 105: 1853-1860.
39. Bhowmik A, Seemungal TA, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
40. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472-478.
41. Perng DW, Tao CW, Su KC, et al. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009; 33: 778-784.